Thyroid eye disease (TED) therapy Tepezza – the best asset in Amgen's $26 billion takeover of Horizon in 2023 – might be dealing with Levels of competition from A neater-to-dose alternate from Sling Therapeutics. The resources will help a Period 2b clinical demo evaluating the bus